Lou Gehrig's Disease or Amyotrophic Lateral Sclerosis (ALS) is a neurological disorder characterized by progressive degeneration of motor neuron cells in the spinal cord and brain, which ultimately results in paralysis and death. The disease takes its less-scientific name from Lou Gehrig, a baseball player with the New York Yankees in the late 1920s and 1930s, who was forced to retire in 1939 as a result of the loss of motor control caused by the disease.
In 1991, a team of researchers linked familial ALS to chromosome 21. Two years later, the SOD1 gene was identified as being associated with many cases of familial ALS. The enzyme coded for by SOD1 carries out a very important function in cells: it removes dangerous superoxide radicals by converting them into non-harmful substances. Defects in the action of this enzyme mean that the superoxide radicals attack cells from the inside, causing their death. Several different mutations in this enzyme all result in ALS, making the exact molecular cause of the disease difficult to ascertain.
Recent research has suggested that treatment with drugs called antioxidants may benefit ALS patients. However, since the molecular genetics of the disease are still unclear, a significant amount of research is still required to design other promising treatments for ALS.
The Salk Institute has been awarded a $10.8 million grant by the California Institute for Regenerative Medicine (CIRM) for translational research focusing on developing a novel stem-cell based therapy for Amyotrophic Lateral Sclerosis (ALS) - or Lou Gehrig's Disease.
Researchers led by Moores UCSD Cancer Center Director Dennis A. Carson, MD, professor of medicine, and Catriona Jamieson, MD, PhD, assistant professor of medicine and director of the Cancer Stem Cell Research Program at the Moores UCSD Cancer Center have been awarded $20 million over four years to develop novel drugs against leukemia stem cells.
New research published in the October 27, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology, suggests that those with both diseases actually have a slower rate of memory loss than people who had only Alzheimer's disease.
A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice. The results offer a bit of good news in efforts to develop a therapy to stop or slow the progression of a disease that generally kills its victims within just a few years.
Johns Hopkins scientists have been awarded a $3.7 million grant from the National Institutes of Health (NIH) to learn more about the nerve and muscle-wasting disease amyotrophic lateral sclerosis (ALS) using stem cells developed from ALS patients' skin. The award, given over a two-year span, will be shared with three other laboratories, including one at Harvard University and two at Columbia University.
For decades, scientists have thought the faulty neural wiring that predisposes individuals to behavioral disorders like autism and psychiatric diseases like schizophrenia must occur during development. Even so, no one has ever shown that a risk gene for the disease actually disrupts brain development.
New guidelines from the American Academy of Neurology identify the most effective treatments for amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease. The guidelines are published in the October 13, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.
Dr. John England, Professor and Chairman of Neurology at LSU Health Sciences Center New Orleans, analyzed research findings and was responsible for the quality and accuracy of evidence analysis and the conclusions of the studies resulting in new guidelines for treating Lou Gehrig's disease, or amyotropic lateral sclerosis (ALS).
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.
Premature aging of the immune system appears to play a role in the development of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to research scientists from the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center, the Weizmann Institute of Science in Israel, and Sheba Medical Center in Israel.
A collaboration between scientists at Vanderbilt University and the University of California, San Francisco has led to the first direct information about the molecular structure of prions. In addition, the study has revealed surprisingly large structural differences between natural prions and the closest synthetic analogs that scientists have created in the lab.
A collaboration between scientists at Vanderbilt University and the University of California, San Francisco has led to the first direct information about the molecular structure of prions. In addition, the study has revealed surprisingly large structural differences between natural prions and the closest synthetic analogs that scientists have created in the lab.
Drivers with mild to moderate Parkinson's disease may be at higher risk of crashes on foggy days and other times of low visibility. The research, involving a driving simulation test, is published in the October 6, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.
Allergan, Inc. today filed a declaratory relief action in the United States District Court for the District of Columbia seeking a ruling that would allow Allergan to proactively share truthful and relevant information with the medical community to assist physicians in evaluating the risks and benefits of BOTOX (onabotulinumtoxinA) for certain “off-label” therapeutic uses.
The AMERIGROUP Foundation teamed up with the ALS Association today in support of a 4K walk, groundbreaking and beach party to benefit the Grommet Island park project - a first of its kind, 100 percent handicap-accessible oceanfront destination - in Virginia Beach.
Unlike other forms of suicide, physician assisted death does not cause substantial regret, or a sense of rejection among surviving family members. In addition, the prevalence and severity of depression and grief among family members whose loved ones received aid in dying is no different than family members whose loved ones did not pursue physician assisted suicide.
Inability to handle financial transactions or manage money may be an early indicator that a person with mild memory problems soon is likely to develop Alzheimer's disease, according to new research from the University of Alabama at Birmingham (UAB) Alzheimer's Disease Center, part of the Department of Neurology.
New research finds poor money management skills may indicate that a person with mild memory problems will soon develop Alzheimer's disease. The study is published in the September 22, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
Insurance companies push speech-impaired patients, like one New York woman with ALS, or Lou Gehrig's disease, to buy expensive computers featuring text-to-speech software by refusing to pay for alternative devices, the New York Times reports. Furthermore, they insist on blocking all other capabilities of the proprietary machines they do cover.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.